New hope for taming tardive Dyskinesia's twitches?

NCT ID NCT07365462

Recruiting now Symptom relief Sponsor: Neurocrine Biosciences Source: ClinicalTrials.gov ↗

First seen Jan 29, 2026 · Last updated May 06, 2026 · Updated 16 times

Summary

This study tests an experimental drug, NBI-1065890, to see if it can reduce the involuntary movements caused by tardive dyskinesia. About 100 adults with conditions like schizophrenia or bipolar disorder who also have moderate to severe tardive dyskinesia will receive either the drug or a placebo. The main goal is to measure changes in movement severity after 8 weeks.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TARDIVE DYSKINESIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Neurocrine Clinical Site
RECRUITING

Chino, California, 91710, United States
Neurocrine Clinical Site
RECRUITING

Torrance, California, 90501, United States
Neurocrine Clinical Site
RECRUITING

Hialeah, Florida, 33012, United States
Neurocrine Clinical Site
RECRUITING

Miami, Florida, 33176, United States
Neurocrine Clinical Site
RECRUITING

Tampa, Florida, 33629, United States
Neurocrine Clinical Site
RECRUITING

Lincoln, Nebraska, 68526, United States

Conditions

Explore the condition pages connected to this study.

TARDIVE DYSKINESIA